Sugi Predict

Sugi Predict / Compounds / SCHEMBL2690338

SCHEMBL2690338

SCHEMBL2690338

C[C@@H]1CCC[C@@H](C=O)N1C(=O)OC(C)(C)C

nearest known ligand 0.44

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ CHRM2 P08172 1/20 0.44
▸ CHRM1 P11229 1/20 0.44
▸ CHRM3 P20309 1/20 0.44
▸ PREP P48147 3/20 0.40
▸ RECQL P46063 1/20 0.38
▸ HPGD P15428 2/20 0.37
▸ CTSK P43235 1/20 0.36
▸ EPHX1 P07099 1/20 0.35
▸ ALDH1A1 P00352 2/20 0.35
▸ GLA P06280 1/20 0.35
▸ NR1H2 P55055 1/20 0.35
▸ KMT2A Q03164 2/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ MAPT P10636 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3075663 1.00 CHRM2 (0.44) CHRM2CHRM1CHRM3PREPRECQL
SCHEMBL2690340 1.00 CHRM2 (0.44) CHRM2CHRM1CHRM3PREPRECQL
SCHEMBL3075660 1.00 CHRM2 (0.44) CHRM2CHRM1CHRM3PREPRECQL
SCHEMBL2690339 1.00 CHRM2 (0.44) CHRM2CHRM1CHRM3PREPRECQL
SCHEMBL19915056 0.90 CHRM2 (0.46) CHRM2CHRM1CHRM3PREPRECQL
SCHEMBL29102381 0.90 CHRM2 (0.46) CHRM2CHRM1CHRM3PREPRECQL
SCHEMBL26143938 0.90 CHRM2 (0.46) CHRM2CHRM1CHRM3PREPRECQL
SCHEMBL220833 0.90 CHRM2 (0.46) CHRM2CHRM1CHRM3PREPRECQL
SCHEMBL622600 0.90 CHRM2 (0.46) CHRM2CHRM1CHRM3PREPRECQL
SCHEMBL26363782 0.90 CHRM2 (0.46) CHRM2CHRM1CHRM3PREPRECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9062007-B2 Cyclic amide BACE-1 inhibitors having a benzamide substituent MERCK SHARP & DOHME CORP. (US) 2015-06-23 — — US disclosed
US-20140128361-A1 CYCLIC AMIDE BACE-1 INHIBITORS HAVING A BENZAMIDE SUBSTITUENT PHARMACOPEIA DRUG DISCOVERY, INC. (US) 2014-05-08 — — US disclosed
US-8623867-B2 Cyclic amine BACE-1 inhibitors having a benzamide substituent MERCK SHARP & DOHME CORP. (US) 2014-01-07 — — US disclosed
US-20130004518-A1 CYCLIC AMINE BACE-1 INHIBITORS HAVING A BENZAMIDE SUBSTITUENT Merck, Sharp & Dohme Corp. (US) 2013-01-03 — — US disclosed
US-8278334-B2 Cyclic amine BACE-1 inhibitors having a benzamide substituent Merck, Sharp & Dohme Corp. (US) 2012-10-02 — — US disclosed
US-8168657-B2 administering a solenopsin derivative such as 2-methyl-6-(2-phenylethyl)piperidine or other piperidine derivatives to treat a tumor or cancer in a patient BOWEN J PHILLIP (US) 2012-05-01 — — US disclosed
US-8168657-B2 administering a solenopsin derivative such as 2-methyl-6-(2-phenylethyl)piperidine or other piperidine derivatives to treat a tumor or cancer in a patient BOWEN J PHILLIP (US) 2012-05-01 — — US disclosed
US-20100152138-A1 CYCLIC AMINE BACE-1 INHIBITORS HAVING A BENZAMIDE SUBSTITUENT SCHERING CORP. 2010-06-17 — — US disclosed
US-7662816-B2 Cyclic amine BACE-1 inhibitors having a benzamide substituent SCHERING CORPORATION (US) 2010-02-16 — — US disclosed
EP-1660443-B1 CYCLIC AMINE BACE-1 INHIBITORS HAVING A BENZAMIDE SUBSTITUENT SCHERING CORP (US) 2009-03-04 — — EP disclosed
US-20050119227-A1 Cyclic amine bace-1 inhibitors having a benzamide substituent SCHERING CORPORATION 2005-06-02 — — US disclosed
US-20050038071-A1 Solenopsin a, b and analogs and as novel angiogenesis inhibitors BOWEN J PHILLIP (US) 2005-02-17 — — US disclosed
WO-2003061598-A2 SOLENOPSIN A, B AND ANALOGS AS NOVEL ANGIOGENESIS INHIBITORS THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) 2003-07-31 — — WO disclosed
EP-1138679-B1 HYDRONAPHTHO 2,3-c]FURAN DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF SAGAMI CHEM RES (JP) 2003-03-19 — — EP disclosed
US-6392059-B1 THERAPY FOR ALZHEIMER'S DISEASE SAGAMI CHEMICAL REASEARCH CENTER (JP) 2002-05-21 — — US disclosed
US-6369078-B1 Solenopsin derivatives and analogues as fire ant suppressants BOWEN J PHILLIP (US) 2002-04-09 — — US disclosed
EP-1138679-A1 HYDRONAPHTHO 2,3-c]FURAN DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF SAGAMI CHEMICAL RESEARCH CENTER (JP) 2001-10-04 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140128361-A1 CYCLIC AMIDE BACE-1 INHIBITORS HAVING A BENZAMIDE SUBSTITUENT BACE1, BACE2, BCHE CHRM2 429/4885CHRM1 428/4885CHRM3 802/4885
US-20100152138-A1 CYCLIC AMINE BACE-1 INHIBITORS HAVING A BENZAMIDE SUBSTITUENT BACE1, BACE2, BCHE CHRM2 261/4885CHRM1 209/4885CHRM3 491/4885
US-20050119227-A1 Cyclic amine bace-1 inhibitors having a benzamide substituent BACE1, BACE2, BCHE CHRM2 261/4885CHRM1 209/4885CHRM3 491/4885
US-20130004518-A1 CYCLIC AMINE BACE-1 INHIBITORS HAVING A BENZAMIDE SUBSTITUENT BACE1, BACE2, BCHE CHRM2 261/4885CHRM1 209/4885CHRM3 491/4885
US-20050038071-A1 Solenopsin a, b and analogs and as novel angiogenesis inhibitors VEGFA, TEK, FLT1 CHRM2 4884/4885CHRM1 4872/4885CHRM3 4885/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.